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Background: The prevalence of diabetes has increased significantly in well-developed 
countries during the last decade and it continues to grow. Diabetes increases the risk of 
restenosis in patients treated percutaneously for peripheral artery disease. The present study 
sought to compare outcomes of atherectomy treatment in diabetic (DM) vs. non-diabetic 
(nDM) patients suffering from peripheral artery disease. 
Method: Between 2008 and 2012, 204 revascularization atherectomy procedures were 
performed on arteries of the lower extremities. The endpoints included target lesion 
revascularization (TLR), amputation and death. The type of atherectomy (excisional-soft 
plaque, orbital-calcified plaque, with active aspiration — with a thrombus) was left to 
operator discretion. 
Results: This study contains 132 DM (66% male, age 68 ± 11.2 years) and 72 nDM (63% 
male, age 75 ± 11.3 years) subjects. DM were younger but had a higher prevalence of 
coronary artery disease (DM: 91% vs. nDM: 62%, p < 0.0001) and end-stage renal disease 
(DM: 22% vs. nDM: 2.5%, p < 0.0001). There were no differences in critical limb ischemia 
between the groups (DM: 21% vs. nDM: 12%, p = 0.13). Mean time of follow-up was 384 
and 411 days in DM and nDM, respectively (p = 0.43). There were no significant differences 
in TLR (DM: 15.2% vs. nDM: 22.2%, p = 0.249), amputations (DM: 3.0% vs. nDM: 1.5%, p 
= NS) or death rates (DM: 2.2% vs. nDM: 2.7%, p = NS). Kaplan-Mayer analysis showed no 
significant differences between the groups in the time to TLR, amputation or death. 
Conclusions: Plaque modification with adjusted atherectomy appears to have similar 
outcomes in diabetic as well as in non-diabetic patients. Nonetheless, a randomized study 
would be warranted to confirm the findings of the current study. 
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 Diabetes mellitus (DM) has a pandemic status in well-developed countries. It is 
projected that DM will have a prevalence of 552 million worldwide by 2030 [1]. The 
strongest risk factors for peripheral artery disease (PAD) are DM and smoking [2]. Whereas 
the ratio of smokers is falling, the DM prevalence continues to increase. The symptomatic 
PAD is observed in 21% of patients with DM [3]. Moreover, DM is also an independent risk 
factor for chronic kidney disease which significantly increases the chance of PAD [4]. Over 
the years multiple therapies for PAD have emerged, including pharmacological regimens, 
endovascular and open surgery, drug-coated balloons (DCB), and stem cell therapy [5]. 
Nevertheless, revascularization of lower limb arteries in patients with DM brings 
disappointing long-term outcomes in comparison to the non-diabetic population [6, 7]. This 
could be caused by the fact that diabetic lesions in diabetic patients occur over a wider area of 
the vasculature, including small-diameter vessels [8]. As a result, the atherectomy type chosen 
based on the plaque morphology and vessel diameter may improve long-term outcomes [9].  
The long-term outcomes of endovascular revascularization of lower limb arteries using 
atherectomy in diabetic patients remains unclear. Therefore, the aim of this study to is 
compare long-term outcomes after endovascular revascularization of lower limb arteries with 




This study is based on a retrospective study of 203 consecutive patients with 
symptomatic PAD who underwent endovascular revascularization with atherectomy between 
2008 and 2012 at San Antonio Endovascular and Heart Institute. 132 patients were diabetic, 
whereas 72 were non-diabetic. 
Adult patients (> 18 years old) with both intermittent claudication (Rutherford 3) and 
critical limb ischemia (CLI; Rutherford 4–6) were included provided they had at least 1 lesion 
with > 70% diameter stenosis confirmed on live quantitative vessel angiography in a lower 
extremity artery. Patients with in-stent restenosis and diabetes type 1 were excluded. 
 
Procedural characteristic and pharmacological regimen 
Directional (Silver HawkTM, Medtronic), orbital (Diamondback 360°, CSI 360°) and 
directional with suction (JetstreamTM, Boston Scientific) atherectomy (AT) devices were 
applied in this study. The type of AT was left to operator discretion, nonetheless directional 
AT was performed in soft and mixed plaques; orbital AT was applied when a lesion appeared 
to be calcified; and directional AT with suction was performed when thrombus was suspected. 
Orbital AT was always followed by the low-pressure balloon post-dilatation; and after 
directional AT, percutaneous transluminal angioplasty (PTA) was performed if residual 
stenosis was > 30%. The Distal protection system was not used for any patient. Angiographic 
success was defined as post-procedural Thrombolysis in Myocardial Infarction (TIMI) 3 flow, 
no dissection or residual stenosis < 30%. If angiographic success was not achieved, bail-out 
stenting was performed. Acetylsalicylic acid (81 mg/day) was continued indefinitely whereas 
clopidogrel (75 mg/day) was advised to be continued for 12 months after the procedure 
together with atorvastatin, at the maximum tolerable dose, usually 40 mg daily. 
 
Atherectomy devices 
The Silver Hawk plaque excision system (Medtronic) is a forward cutting directional 
AT device. The device consists of a rotating blade inside a tubular housing with a collection 
space in the nose cone. The device enables the performance of AT in vessels with a diameter 
of 1.5–7 mm. 
Diamondback 360° (CSI360°) is an orbital AT system tipped with an eccentric, 
diamond-coated crown. The crown rpm can vary from 60,000 to 200,000. The crown may be 
advanced forward and backward when it is intra-arterial. The needed diameter is achieved by 
increasing the speed of rotation. Faster speeds result in an increased centrifugal force, yielding 
a larger orbit, and this device is recommended for calcified lesions. Usually, orbital AT is 
performed before stenting/balloon angioplasty. 
The Pathway Jetstream PV Atherectomy System (Boston Scientific) is a rotational AT 
device with a front-cutting tip that spins at 60–70,000 rpm. Jetstream® expandable catheters 
have a catheter tip that remains at a diameter of 2.1–2.4 mm when rotating clockwise and 2.4–
3.4 mm when rotating counterclockwise. For below the knee interventions this device is 
available in a fixed size: 1.6 mm and 1.85 mm. This is the only AT device on the market with 
active aspiration. The derbies as well as thrombus are collected in a bag located on the 
console device, outside the body. 
 
Study endpoints and definitions 
Because of the observational nature of this study, no preliminary hypothesis was 
generated. Target lesion revascularization (TLR) was considered a primary endpoint and was 
defined as any symptom-driven revascularization within a previously treated segment. 
Unplanned amputation related to a previously treated vessel, death and a change in the 
Rutherford class were regarded as secondary endpoints. Furthermore, incidents of vessel 
perforation, dissection and distal embolization, and bailout stenting were collected. 
 
Safety and ethics 
This retrospective study was conducted in accordance with standard ethics guidelines. 
Endovascular procedures were carried out by experienced interventional cardiovascular teams 
in a high-volume center with a vascular surgery back up within 30 min of transportation. 
Owing to the observational and retrospective nature of this study, neither  patient 
consent nor ethics committee approval was required. 
 
Data collection and follow-up 
Clinical and procedural data were collected on case report forms generated by the 
hospital electronic system, containing all patient hospitalization and discharge information. 
This system is audited for institutional quality assurance by private insurance companies and 
the state health fund. 
Long-term follow-up data were collected during ambulatory check-ups or over the 
phone. The follow-up office visits were usually scheduled every 3–5 months. Some patients 
had phone consultations due to a lack of symptoms, and office-based follow-ups were 
scheduled on a further date. All outcomes of interest were confirmed using hospital discharge 




Continuous variables are presented as mean ± standard deviation or median 
(interquartile range [IQR]). Data were compared using the t-test for parametric or Mann-
Whitney U-test for non-parametric continuous variables. Categorical variables are reported as 
frequencies (percentages) and were compared using the χ2 or Fisher exact test, as appropriate. 
Survival curves were constructed using the Kaplan-Meier estimates and were compared with 
the log-rank test. All reported p-values are two-tailed, and p < 0.05 was considered as 
significant. GraphPad 6 Prism was used for statistical analysis. 
 
RESULTS 
The method of diabetes control was primarily oral agents (56.3%, n = 73) followed by 
insulin injections (36.6%, n = 48) or a combination of both (8.3%, n = 11). Patients in the 
diabetic cohort were significantly younger but had considerably more risk factors including 
off-range body mass index (BMI), coronary artery disease, artery bypass grafting (CABG), 
percutaneous coronary interventions (PCI) and dialysis-dependent renal insufficiency (Table 
1). The mean time of follow-up was 384 and 411 days in DM and nDM, respectively (p = 
0.43). 
Lesion characteristics were similar in DM (n = 198) and nDM (n = 106) patients with 
a mean number of lesions per patient equaling 1.5 in both groups. Lesion location was 
primarily superficial femoral artery in nDM (33%, n = 38), whereas in the DM cohort anterior 
tibial artery was most frequently revascularized (29.7%, n = 59). There were no significant 
differences in target lesions between the groups. Furthermore, there were no differences 
between the groups in terms of lesion morphology in the TransAtlantic Inter-Society 
Consensus (TASC) and the number of total chronic occlusion. There were no significant 
differences between the groups in the choice of atherectomy, except for JetStream in favor in 
the case of the nDM group (Table 2). 
The number of periprocedural complications was similar between the groups. The 
detailed periprocedural outcomes are shown in Table 3. 
At follow-up there were no differences between the groups in TLR after 6 months 
(DM: 7.5% vs. nDM 2.8%, p = 0.224), 12 months (DM: 13.6% vs. nDM 20.8%, p = 0.232) or 
24 months (DM: 15.2% vs.  nDM 22.2%, p = 0.249) as shown in Figure 1. The amputation 
and death ratios were comparable between the groups (DM: 3% vs. nDM 1.5%, p = NS) and 
(DM: 2.2% vs. nDM 2.7%, p = NS) respectively, as also shown in Figure 1. In the Kaplan-
Mayer analysis, there were no differences in TLR-free survival, amputation free survival and 
survival (p = 0.27, hazard ratio [HR] 0.714, 95% confidence interval [Cl] 0.371–1.314; p = 
0.81, HR 0.8, 95% Cl 0.127–5.041; p = 0.557, HR 4.542, 95% Cl 0.562–36.69) respectively, 
as shown in Figure 2. Moreover, there were no differences in the TLR between the groups 
depending on the artery and type of atherectomy device. 
There were no significant differences in the Rutheford class between the groups during 
follow-up. However, there was a significant drop in the Rutherford class between groups 
before and after revascularization (< 0.0001) as shown in Figure 3. 
 DISCUSSION 
The current study presents a direct observational comparison of patients revascularized 
with atherectomy chosen based on plaque morphology in DM and nDM patients. According 
to available research, the present study, for the first-time, describes a direct comparison of 
long-term outcomes for different types atherectomies in diabetics versus non-diabetics in 
claudicates as well as in critical limb ischemia patients. In this study, despite some 
discrepancies in patient baseline characteristics in favor of the nDM group, there were no 
differences in periprocedural complications, target lesion revascularization, amputation or 
death. It should be noted that the DM group consisted of high-risk patients for major 
cardiovascular adverse events due to numerous risk factors like end-stage renal disease, 
advanced coronary artery disease and obesity. Moreover, lesion characteristics are 
comparable between the groups. The difficulties treating PAD in diabetic patients have been 
driven by numerous factors including diffuse atherosclerosis causing longer lesions with 
smaller diameter lumen, more calcifications and greater plaque burden [10]. Furthermore, DM 
is associated with a more severe below-the-knee PAD, whereas risk factors, such as smoking, 
are associated with more proximal lesions [8]. 
There is very little data comparing long-term outcomes after treatment in patients with 
DM vs. nDM in PAD. A sub-analysis of Definitive Le comparing revascularization with 
SliverHawk/TurboHawk in diabetics and non-diabetics showed that directional atherectomy is 
equally effective in both groups of patients [11]. The ratio of target lesion revascularization 
was similar between the groups at 12-month follow-up and equaled 83.8% and 87.5% for 
diabetics and non-diabetics respectively. Just as in our database, the revascularization in 
Definitive Le was more frequent in case of below the knee procedures and the characteristics 
of demographics were similar. Nevertheless, in the Definitive Le study patients with critical 
limb ischemia were excluded. Lee et al. [6] compared the efficiency of plain old balloon 
angioplasty (POBA) in DM and nDM patients [6]. This study with a 2-year follow-up showed 
that POBA is less effective in diabetic patients, with a higher rate of restenosis and 
amputations. On the other hand, the drug eluting balloon (DEB) in the small study showed 
better outcomes in comparison to POBA in below-the-knee lesions at 3-month follow-up. 
Nevertheless, no benefits of DEB after 12 months were reported [12]. While comparing the 
stent technology, the Zilver PTX study reported that DM and nDM cohorts in their study had 
similar outcomes using the paclitaxel eluting stent [13]. Nonetheless, only superficial femoral 
artery was included as the target vessel. Darling et al. [7] published a direct comparison of 
diabetics and non-diabetics treated with POBA or  bypass surgery in CLI patients. According 
to observations of this group, diabetics manifested an increased risk of long-term mortality, 
incomplete wound healing, a major amputation and restenosis, especially after POBA in 
comparison to non-diabetics. Furthermore, Dick et al. [14] published a study with results 
similar to the study mentioned earlier. 
There is an interesting technology that may by combined with atherectomy in PAD 
and it is the local drug delivery after revascularization. Early reports on the combination of 
plaque modification with atherectomy and subsequent DEB seem to be promising [15, 16]. 
Novel technologies, including local drug delivery nano-technology, may soon become 
available for follow-up treatment of plaque modifications after atherectomy [17]. 
All patients in this study were also treated pharmacologically to reduce any major 
cardiovascular adverse events. Despite encouraging data on including ciliostazol in the 
treatment after stenting of femoropopliteal region [18], almost all the present patients were on 
dual antiplatelet therapy (DAPT) consisting of clopidogrel (75 mg) and acetylsalicylic acid 
(81 mg) once a day. Dual antiplatelet therapy was prescribed due to the fact that after AT, the 
intima-media could be exposed to blood flow, significantly increasing the risk of acute or 
subacute thrombosis [19]. 
 To summarize, this study shows that the outcomes of atherectomy in PAD are similar 
in DM patients as compared to nDM patients. The large minimal lumen diameter obtained 
during atherectomy may play a crucial role in this phenomenon, which translates into a lower 
TLR ratio at follow-up in diabetics as well as non-diabetics. 
 
Limitations of the study 
The main drawbacks of this analysis are those inherent to any single-center, 
observational study [20], along with differences in baseline patient characteristics. 
Nevertheless, the differences arise from the character of DM and nDM patients. The exact 
data on very long below the knee chronic total occlusion are unavailable. The ABI, USG, 
Doppler and toe pressure were not performed on each visit, making this data unsuitable for 
statistical analysis. This study is hypothesis-generating only. 
 CONCLUSIONS 
In this hypothesis-generating study of patients with lower extremity PAD, plaque 
modifications with adjusted atherectomies appear to have similar outcomes in diabetic as well 
as in non-diabetic patients. Nevertheless, this should be confirmed in further controlled 
randomized trials. 
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Number 72 132 
 
Male 46 (63%) 88 (66%) 0.7 
Age 75 ± 11.3 68 ± 11.2 0.0001 
Body mass index 26.5 ± 4.9 29.4 ± 4.8 < 0.0001 
Coronary artery bypass grafting 10 (14%) 56 (42%) < 0.0001 
Percutaneous coronary intervention 30 (41%) 79 (60%) 0.0185 
Previously revascularized peripheral 
artery disease 
1 (5.5%) 8 (6.0%) 0.163 
Arterial hypertension 71 (99%) 132 (100%) 0.9 
Coronary artery disease 45 (62%) 119 (91%) < 0.0001 
Critical limb ischemia 9 (12%) 28 (21%) 0.1332 
Dialysis reliant 2 (2.5%) 42 (22%) < 0.0001 
Smokers 11 (15%) 23 (17.4%) 0.8445 








Number 106 198  
Iliac 0 1 (0.5%) 1.0 
Common femoral artery 1 (0.94%) 1 (0.5%) 1.0 
Superficial femoral artery 38 (35.8%) 41 (20.7%) 0.064 
Profunda femoral artery 0 1 (0.05%) 1.0 
Popliteal artery 9 (8.4%) 23 (11.6%) 0.09 
Anterior tibial artery 20 (18.8%) 59 (29.7%) 0.265 
Trunk 5 (4.9%) 13(6.5%) 0.471 
Peroneal artery 10 (9.4%) 18(9%) 0.51 
Dorsalis pedis 3 (2.8%) 5 (2.5%) 0.173 
Calcaneal artery 3 (2.8%) 5 (2.5%) 0.173 
Above the knee 49 67  
Below the knee 57 131  
Graft 1 8 0.086 
Pre-procedure (% diameter stenosis) 89.7% 93.7% 0.386 
Mean lesion length [mm] 76  23 81  19 0.148 
TASC A 18 (36.7%) 24 (35.8%) 1.0 
TASC B 15 (30.6%) 18 (26.9%) 0.681 
TASC C 11 (22.5%) 17 (25.4%) 0.827 
TASC D 5 (10.2%) 8 (11.9%) 1.00 
Chronic total occlusion 20 (18.8%) 56 (28.2%) 0.073 
JetStrem G2 9 (12,5%) 4 (3%) 0.0137 
CSI360 20 (27,5%) 46 (34%) 0.3489 
Silver Hawk 43 (50%) 82 (62%) 0.6549 
TASC — TransAtlantic Inter-Society Consensus 
 
  


















Artery perforation 1 (1.3%) 0 (0%) 1.0 
Distal embolization 0 (0%) 1 (0.7%) 1.0 
Flow limiting dissection 2 (2.7%) 2 (1.4%) 1.0 
Bailout stenting 2 (2.7%) 2 (1.4%) 1.0 
 Figure 1. Target lesion revascularization (A), amputation and death (B) ratio. 
 
Figure 2. Kaplan-Mayer curves showing target lesion revascularization free survival time 
(A), amputation free survival time (B) and survival time (C). 
 
Figure 3. Rutherford classification prior and after treatment. 
 



